Effect of Prior Cancer on Trial Eligibility and Treatment Outcomes in Nasopharyngeal Carcinoma: Implications for Clinical Trial Accrual

被引：0
|
作者：
Wang, Ya-Qin [1 ]
Lv, Jia-Wei [1 ]
Tang, Ling-Long [1 ]
Du, Xiao-Jing [1 ]
Chem, Lei [1 ]
Li, Wen-Fei [1 ]
Liu, Xu [1 ]
Guo, Ying [2 ]
Lin, Ai-Hua [3 ]
Mao, Yan-Ping [1 ]
Sun, Ying [1 ]
Chen, Yu-Pei [1 ]
Ma, Jun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-4006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4006
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility Criteria Reply
    Hope, Thomas A.
    Calais, Jeremie
    JAMA ONCOLOGY, 2022, 8 (04)
  • [32] Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials
    Oakley, Clayton K.
    Yellala, Amulya
    Tulpule, Sunil
    High, Robin
    Kishor, Apar
    Marr, Alissa S.
    ONCOLOGY-NEW YORK, 2024, 38 (12):
  • [33] QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care
    Tri Le
    Yang, Hui
    Rashdan, Sawsan
    Link, Mark S.
    Zaha, Vlad G.
    Alvarez, Carlos
    Gerber, David E.
    CLINICAL LUNG CANCER, 2020, 21 (01) : 21 - +
  • [34] Impact of eligibility criteria discordance on clinical trial accrual in diffuse large B-cell lymphoma (DLBCL).
    Anderson, Clare E.
    Wang, Mei
    Wuliji, Natalie
    Patel, Anand Ashwin
    Lin, Chenyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design
    Pusztai, L.
    BREAST CANCER RESEARCH, 2009, 11 : S2 - S3
  • [36] Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design
    L Pusztai
    Breast Cancer Research, 11
  • [37] Adjuvant treatment and outcomes in patients with stage III colon cancer (CC) who do not fit clinical trial eligibility criteria (CTEC)
    Javaheri, Khodadad Rasool
    Kennecke, Hagen F.
    Renouf, Daniel John
    Lim, Howard John
    Hsu, Tina
    Speers, Caroline
    Goktepe, Ozge
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [38] The impact of clinical stage on renal cell carcinoma outcomes: Implications for neoadjuvant trial design
    Ball, Mark Wayne
    Gorin, Michael A.
    Pierorazio, Phillip M.
    Hammers, Hans J.
    Harshman, Lauren Christine
    Drake, Charles G.
    Allaf, Mohamad E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [39] Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual
    St Germain, Diane
    Denicoff, Andrea M.
    Dimond, Eileen P.
    Carrigan, Angela
    Enos, Rebecca A.
    Wilkinson, Kathy
    Mathiason, Michelle A.
    Duggan, Brenda
    Einolf, Shaun
    McCaskill-Stevens, Worta
    Bryant, Donna M.
    Thompson, Michael A.
    Grubbs, Stephen S.
    Go, Ronald S.
    JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (02) : E73 - E80
  • [40] AGE AS A CRITERION FOR ELIGIBILITY IN A LUNG-CANCER CLINICAL-TRIAL
    LEE, JY
    MARKS, JE
    SIMPSON, JR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (04): : 449 - 452
12345